Why Europe’s CDMO Sector Must Learn to Dance with Disruption
-
by Joe Renny
January 14, 2026
-
5 min
8 Key Takeaways
-
1
Antifragility allows organizations to thrive on adversity.
-
2
CDMOs can redefine their roles in biopharma.
-
3
The Biosecure Act affects pharmaceutical trade.
-
4
Emphasis on modular and digital production is vital.
-
5
ESG compliance offers competitive advantages in Europe.
-
6
Disruption should be seen as a growth opportunity for CDMOs.
-
7
Europe is not declining; it is evolving industrially.
-
8
Crisis can turn into opportunity when strategically navigated.
The European CDMO sector stands at a pivotal moment defined by disruption from inflation, geopolitical changes, and health crises. These challenges present opportunities for growth through antifragility, a concept advocating that organizations can thrive on adversity. By stepping beyond the subcontractor role, CDMOs can secure their importance in the biopharma ecosystem. They must exploit their strengths in high-value production and regulatory credibility to thrive amidst disruptions like Brexit and the Biosecure Act, framing these challenges as pathways to a resilient future.
Listen Tab content
